Investor Relations News2022-06-02【中国证券报】: 惠升生物完成5亿元A轮融资国寿大健康基金领投 http://csapp.cs.com.cn/zzb-h5/stock_news_detail.html?id=232596&origin=1&share_flag=1PreviewPreviousXUANZHU BIOPHARM ENTERED INTO AN EXCLUSIVE LICENSING AGREEMENT WITH NEW ASIA PHARMACEUTICAL FOR THE DEVELOPMENT AND COMMERCIALIZATION OF BENAPENEM AND PLAZOMINCIN IN THE GREATER CHINA TERRITORYNextHuisheng Biopharmaceutical Announced the Successful Completion of Round A Financing Create Value via Full Product Pipeline in Diabetes and Complications
